On 10 November 2025, Bio-Thera announced that it has entered into an exclusive commercialisation and licence agreement with Dr Reddy’s in relation to BAT2306, biosimilar to Novartis’ Cosentyx® (secukinumab). Under the agreement, Bio-Thera will have responsibility for developing, manufacturing and supplying BAT2306, while Dr Reddy’s will be responsible for regulatory approvals and commercialisation in Southeast Asian countries, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand and Vietnam.
Bio-Thera completed a phase 3 clinical trial of BAT2306 in plaque psoriasis in 2024, and a phase 1 trial in 2023. Secukinumab biosimilars are also under development by Celltrion (phase 1 clinical trial completed; global phase 3 trial for CT-P55 in plaque psoriasis approved by the FDA in August 2024), Taizhou Mabtech Pharmaceutical (phase 1 trial of CMAB015 completed in 2023) and Livzon Pharmaceutical Group (phase 3 clinical trial of LZM012 in plaque psoriasis, status unknown).
Bio-Thera & Dr Reddy’s have previously partnered on biosimilars in SE Asia. In March 2025, Bio-Thera and Dr Reddy’s announced exclusive commercialisation agreements for BAT2206 and BAT2306, biosimilars to J&J/Janssen’s Stelara® (ustekinumab) and Simponi® (golimumab), respectively, in SE Asia.